Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
NGM Biopharmaceuticals appoints Siobhan Nolan Mangini CFO » 16:16
05/27/20
05/27
16:16
05/27/20
16:16
NGM

NGM Biopharmaceuticals

$20.24 /

-0.44 (-2.13%)

NGM Biopharmaceuticals…

NGM Biopharmaceuticals announced the appointment of Siobhan Nolan Mangini as CFO. In her role as CFO, which will take effect on July 13, Nolan Mangini will oversee finance, business development and investor relations at NGM. Nolan Mangini most recently served as President and CFO of Castlight Health.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

NGM NGM Biopharmaceuticals
$20.24 /

-0.44 (-2.13%)

Tuesday
Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 14:25
05/26/20
05/26
14:25
05/26/20
14:25
AKRO

Akero Therapeutics

$24.92 /

+0.71 (+2.93%)

, ALT

Altimmune

$8.45 /

+1.51 (+21.76%)

, ENTA

Enanta

$55.90 /

+0.78 (+1.42%)

, GLMD

Galmed

$5.51 /

-0.29 (-5.00%)

, GNFT

Genfit

$5.26 /

+0.02 (+0.38%)

, HEPA

Hepion Pharmaceuticals

$1.94 /

-0.05 (-2.51%)

, ICPT

Intercept

$77.59 /

-2.95 (-3.66%)

, MDGL

Madrigal Pharmaceuticals

$123.16 /

-2.67 (-2.12%)

, NGM

NGM Biopharmaceuticals

$21.22 /

+1.04 (+5.15%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$8.45 /

+1.51 (+21.76%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.90 /

+0.78 (+1.42%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.51 /

-0.29 (-5.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.26 /

+0.02 (+0.38%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.94 /

-0.05 (-2.51%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$77.59 /

-2.95 (-3.66%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GLMD Galmed
$5.51 /

-0.29 (-5.00%)

ENTA Enanta
$55.90 /

+0.78 (+1.42%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

MDGL Madrigal Pharmaceuticals
$123.16 /

-2.67 (-2.12%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

GNFT Genfit
$5.26 /

+0.02 (+0.38%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

NGM NGM Biopharmaceuticals
$21.22 /

+1.04 (+5.15%)

ICPT Intercept
$77.59 /

-2.95 (-3.66%)

ALT Altimmune
$8.45 /

+1.51 (+21.76%)

AKRO Akero Therapeutics
$24.92 /

+0.71 (+2.93%)

Conference/Events
Roth Capital biotech analysts to hold an analyst/industry conference call » 09:42
05/26/20
05/26
09:42
05/26/20
09:42
AKRO

Akero Therapeutics

$24.21 /

+ (+0.00%)

, ALT

Altimmune

$6.94 /

+ (+0.00%)

, ENTA

Enanta

$55.12 /

+ (+0.00%)

, GLMD

Galmed

$5.80 /

+ (+0.00%)

, GNFT

Genfit

$5.24 /

+ (+0.00%)

, HEPA

Hepion Pharmaceuticals

$1.99 /

+ (+0.00%)

, ICPT

Intercept

$80.54 /

+ (+0.00%)

, MDGL

Madrigal Pharmaceuticals

$125.83 /

+ (+0.00%)

, NGM

NGM Biopharmaceuticals

$20.18 /

+ (+0.00%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Eric Lawitz, discuss Non-Alcoholic SteatoHepatitis (NASH) on an Analyst/Industry conference call to be held on May 26 at 3 pm.

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
03/02/20 H.C. Wainwright
Akero Therapeutics initiated with a Buy at H.C. Wainwright
02/13/20 Roth Capital
Akero Therapeutics price target raised to $43 from $34 at Roth Capital
02/10/20 Canaccord
Akero Therapeutics initiated with a Buy at Canaccord
ALT Altimmune
$6.94 /

+ (+0.00%)

05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
02/24/20
Fly Intel: Top five analyst initiations
ENTA Enanta
$55.12 /

+ (+0.00%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
GLMD Galmed
$5.80 /

+ (+0.00%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley FBR
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley FBR
Galmed downgraded to Neutral from Buy at B. Riley FBR
05/15/20 H.C. Wainwright
Galmed price target lowered to $29 from $34 at H.C. Wainwright
GNFT Genfit
$5.24 /

+ (+0.00%)

05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
HEPA Hepion Pharmaceuticals
$1.99 /

+ (+0.00%)

03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
11/07/19 Roth Capital
Hepion Pharmaceuticals initiated with a Buy at Roth Capital
ICPT Intercept
$80.54 /

+ (+0.00%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/27/20 Citi
NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi
NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GLMD Galmed
$5.80 /

+ (+0.00%)

ENTA Enanta
$55.12 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$125.83 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

GNFT Genfit
$5.24 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

NGM NGM Biopharmaceuticals
$20.18 /

+ (+0.00%)

ICPT Intercept
$80.54 /

+ (+0.00%)

ALT Altimmune
$6.94 /

+ (+0.00%)

AKRO Akero Therapeutics
$24.21 /

+ (+0.00%)

Over a week ago
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:39
05/22/20
05/22
12:39
05/22/20
12:39
NVDA

Nvidia

$359.38 /

+8.37 (+2.38%)

, HPE

HP Enterprise

$9.21 /

-1.14 (-11.01%)

, DE

Deere

$144.73 /

+1.92 (+1.34%)

, IBM

IBM

$117.75 /

-1.37 (-1.15%)

, BABA

Alibaba

$201.61 /

-10.39 (-4.90%)

, SPLK

Splunk

$184.26 /

+20.99 (+12.86%)

, RAMP

LiveRamp

$48.51 /

+9.81 (+25.35%)

, ELF

e.l.f. Beauty

$16.46 /

+1.9 (+13.05%)

, AMRN

Amarin

$7.16 /

-0.125 (-1.72%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, ICPT

Intercept

$79.55 /

-12 (-13.11%)

The S&P and Dow are a…

Open Full Text

ShowHide Related Items >><<
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

05/22/20 JPMorgan
Nvidia price target raised to $405 from $305 at JPMorgan
05/22/20 Rosenblatt
Nvidia price target raised to $400 from $340 at Rosenblatt
05/22/20 Raymond James
Nvidia price target raised to $370 from $330 at Raymond James
05/22/20 Craig-Hallum
Nvidia price target raised to $335 from $300 at Craig-Hallum
HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Raymond James
HP Enterprise downgraded to Market Perform from Outperform at Raymond James
05/22/20 Morgan Stanley
Second quarter 'not yet a bottom' for HP Enterprise, says Morgan Stanley
05/22/20 Citi
HP Enterprise earnings call leaves more questions than answers, says Citi
DE Deere
$144.73 /

+1.92 (+1.34%)

05/22/20 Goldman Sachs
Goldman Sachs sees Deere shares outperforming today after earnings
05/20/20 Citi
Deere price target lowered to $145 from $155 at Citi
04/20/20 OTR Global
Farm Equipment Manufacturers downgraded to Negative at OTR Global
04/20/20 Stephens
USDA aid package a positive for Large Ag, says Stephens
IBM IBM
$117.75 /

-1.37 (-1.15%)

04/21/20 Morgan Stanley
Krishna years away from returning IBM to sustainable growth, says Morgan Stanley
04/21/20 Wedbush
IBM price target lowered to $140 from $155 at Wedbush
04/17/20 BMO Capital
IBM price target lowered to $135 from $155 at BMO Capital
04/15/20 Credit Suisse
IBM price target lowered to $150 from $173 at Credit Suisse
BABA Alibaba
$201.61 /

-10.39 (-4.90%)

05/22/20 Goldman Sachs
Goldman Sachs keeps Buy rating on Alibaba after better than expected Q4
04/09/20 Morgan Stanley
Alibaba 'core of core' revenue recovery outlook improved, says Morgan Stanley
03/23/20 Oppenheimer
Tencent, Baidu, Alibaba attractive at current levels, says Oppenheimer
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

05/22/20 JPMorgan
Splunk price target raised to $190 from $174 at JPMorgan
05/22/20 Raymond James
Splunk price target raised to $185 from $140 at Raymond James
05/22/20 Oppenheimer
Splunk price target raised to $190 from $145 at Oppenheimer
05/22/20 BMO Capital
Splunk price target raised to $190 from $177 at BMO Capital
RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

05/22/20 Morgan Stanley
LiveRamp can reset expectations after guidance withdrawal, says Morgan Stanley
05/22/20 Susquehanna
LiveRamp price target raised to $60 from $50 at Susquehanna
04/27/20 Needham
LiveRamp price target lowered to $57 from $70 at Needham
04/21/20 Berenberg
LiveRamp initiated with a Buy at Berenberg
ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

05/22/20 SunTrust
e.l.f. Beauty price target raised to $20 from $15 at SunTrust
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
02/06/20 Piper Sandler
e.l.f. Beauty price target raised to $23 from $19 at Piper Sandler
AMRN Amarin
$7.16 /

-0.125 (-1.72%)

05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
ICPT Intercept
$79.55 /

-12 (-13.11%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

SPLK Splunk
$184.26 /

+20.99 (+12.86%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

Recommendations
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR » 11:48
05/22/20
05/22
11:48
05/22/20
11:48
ICPT

Intercept

$78.50 /

-13.05 (-14.25%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani is a buyer of Intercept Pharmaceuticals on today's selloff. The delay to the FDA panel meeting is "slight," says Mamtani, who has a Buy rating on the shares with a $158 price target. Intercept in midday trading is down 13% to $79.36.

ShowHide Related Items >><<
ICPT Intercept
$78.50 /

-13.05 (-14.25%)

ICPT Intercept
$78.50 /

-13.05 (-14.25%)

05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
ICPT Intercept
$78.50 /

-13.05 (-14.25%)

ICPT Intercept
$78.50 /

-13.05 (-14.25%)

ICPT Intercept
$78.50 /

-13.05 (-14.25%)

ICPT Intercept
$78.50 /

-13.05 (-14.25%)

Downgrade
Intercept downgraded at Raymond James after OCA NDA is postponed » 10:51
05/22/20
05/22
10:51
05/22/20
10:51
ICPT

Intercept

$77.51 /

-14.04 (-15.34%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse downgraded Intercept to Outperform from Strong Buy with a price target of $115, down from $145. While Seedhouse ultimately expects OCA to receive accelerated approval for non-cirrhotic NASH with fibrosis, the delay to a planned virtual AdCom meeting undoubtedly increases perceived risk to approval and appears to ensure the current PDUFA date of June 26 will be again delayed by 3 months. Seedhouse lowered the probability of approval for OCA in NASH from 90% to 80%.

ShowHide Related Items >><<
ICPT Intercept
$77.51 /

-14.04 (-15.34%)

ICPT Intercept
$77.51 /

-14.04 (-15.34%)

05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
05/12/20 Baird
Intercept competitor trial failure a positive, says at Baird
ICPT Intercept
$77.51 /

-14.04 (-15.34%)

ICPT Intercept
$77.51 /

-14.04 (-15.34%)

ICPT Intercept
$77.51 /

-14.04 (-15.34%)

ICPT Intercept
$77.51 /

-14.04 (-15.34%)

Downgrade
Intercept downgraded to Outperform from Strong Buy at Raymond James » 10:39
05/22/20
05/22
10:39
05/22/20
10:39
ICPT

Intercept

$78.26 /

-13.295 (-14.52%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse downgraded Intercept to Outperform from Strong Buy with a price target of $115, down from $145.

ShowHide Related Items >><<
ICPT Intercept
$78.26 /

-13.295 (-14.52%)

ICPT Intercept
$78.26 /

-13.295 (-14.52%)

05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
05/12/20 Baird
Intercept competitor trial failure a positive, says at Baird
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
ICPT Intercept
$78.26 /

-13.295 (-14.52%)

ICPT Intercept
$78.26 /

-13.295 (-14.52%)

ICPT Intercept
$78.26 /

-13.295 (-14.52%)

ICPT Intercept
$78.26 /

-13.295 (-14.52%)

Recommendations
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel » 09:36
05/22/20
05/22
09:36
05/22/20
09:36
ICPT

Intercept

$91.55 /

-0.5 (-0.54%)

Stifel analyst Derek…

Stifel analyst Derek Archila reiterates his Hold rating on Intercept shares after news that the FDA postponed the advisory committee meeting for OCA in NASH that had been tentatively scheduled for June 9. The FDA is requesting additional data and although he believes the impact of a slight delay is modest, he thinks the uncertainty the delay creates, plus the lack of clarity around the additional data requested, will negatively impact near-term sentiment, Archila tells investors. While he ultimately believes OCA will likely gain approval in NASH, he doesn't know how long of a delay this could be, the analyst added.

ShowHide Related Items >><<
ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
05/12/20 Baird
Intercept competitor trial failure a positive, says at Baird
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

Recommendations
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR » 08:54
05/22/20
05/22
08:54
05/22/20
08:54
MDGL

Madrigal Pharmaceuticals

$119.46 /

-2.52 (-2.07%)

, GNFT

Genfit

$5.26 /

-0.16 (-2.95%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on Madrigal Pharmaceuticals (MDGL) to $174 from $134 and keeps a Buy rating on the shares. After hosting a call with Dr. Stephen Harrison from Pinnacle Clinical Research on recent advances in clinical development of therapeutics in non-alcoholic steatohepatitis, the analyst believes the high placebo response in Genfit's (GNFT) Phase III trial is bullish for Madrigal.

ShowHide Related Items >><<
MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/05/20 Chardan
Madrigal Pharmaceuticals initiated with a Buy at Chardan
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
GNFT Genfit
$5.26 /

-0.16 (-2.95%)

05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
05/13/20 Kepler Cheuvreux
Genfit downgraded to Reduce from Buy at Kepler Cheuvreux
05/12/20 B. Riley FBR
Genfit downgraded to Neutral from Buy at B. Riley FBR
05/12/20 Roth Capital
Genfit price target lowered to EUR 13 from EUR 70 at Roth Capital
MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

MDGL Madrigal Pharmaceuticals
$119.46 /

-2.52 (-2.07%)

GNFT Genfit
$5.26 /

-0.16 (-2.95%)

Hot Stocks
Intercept selloff intensifies, shares now down 16% to $77.01  08:19
05/22/20
05/22
08:19
05/22/20
08:19
ICPT

Intercept

$91.55 /

-0.5 (-0.54%)

 
ShowHide Related Items >><<
ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

05/12/20 Citi
Intercept downgraded to Neutral from Buy at Citi
05/12/20 Baird
Intercept competitor trial failure a positive, says at Baird
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

ICPT Intercept
$91.55 /

-0.5 (-0.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.